Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

As an increasing amount of people with high CD4 cell count and low viral load are treated at an early stage of the disease, the treatment paradigm should shift from lifelong triple therapy to a controlled viral load in the plasma and a controlled replication in the reservoirs. If other strategies with less drugs are validated, people living with HIV (PLHIV) will be less exposed to ARVs and if monitoring is needed less frequently, the cost will also diminish. This is an important paradigm shift that merits strong and considered discussion. This session, aimed at clinicians, policy-makers and PLHIV, updates participants on the most recent results and gives them a better understanding of who is most likely to benefit from such a shift in treatment paradigms.

11:00
WESY0301
Introduction
11:10
WESY0302
Treatment initiation: what to expect from dual- or mono-therapy
Christine Katlama, Hôpital Pitié Salpétière / Sorbonne Universités Paris, France
Slides
11:20
WESY0303
Treatment 4 or 5 days a week, for whom is it a suitable option?
Anna Turkova, UCL, United Kingdom
Slides
11:30
WESY0304
Lowering the doses of antiretroviral drugs: what have we learnt from the studies of efavirenz and protease inhibitors?
Kiat Ruxrungtham, The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thailand
Slides
11:40
WESY0305
Monotherapy or dual therapy in switch studies: which is the best regimen?
José Arribas, Hospital La Paz, Spain
Slides
11:50
WESY0306
Moderated discussion
12:20
WESY0307
Closing remarks